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Cytochromes P450s are present in all forms of life and play an important role in 
the oxidative transformation of endogeneous and exogeneous molecules. P450 2E1 is a 
major isoform of cytochrome. The consumption of herbal products in the world is 
increasing greatly during last decade. The concurrent use of herbal products with 
prescription carries a risk for unanticipated adverse herb-drug pharmacokinetic 
interaction, particularly as a result of cytochrome P450 2E1 inhibition.  
In this research, the preparation and purification of extract of Green Tea, 
Goldenseal, Echinacea and Spilanthes was performed. In addition, P450 2E1 related 
activities were to be examined with respect to inhibition by four potential different 
inhibitors, including GTE, Goldenseal, Echinacea and Spilanthes. The objective of this 
research is to determine whether herbal products, such as GTE, Goldenseal, Echinacea 
and Spilanthes, inhibit the activity of the human P450 2E1 enzymes.
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CHAPTER I  
INTRODUCTION 
1.1 Cytochrome P450 and P450 2E1 
1.1.1 Cytochrome P450: General overview 
Cytochrome P450s were discovered in 1955 by Axelrod and Brodie[1]. In 1958 
Garfinkel and Klingenberg detected a CO binding pigment in liver microsomes, which 
had a maximum at wavelength 450nm [2]. From electron spin resonance spectroscopy, 
we know that P450s are a low spin ferric hemoproteins [3] with a cysteine thiol as an 
axial ligand [4, 5, 6]. P450s have two major classes: bacterial /mitochondrial (type I), and 
microsomal (type II) [7]. Many members of this family play a key role in the oxidative 
transformation of endogeneous and exogeneous molecules [8, 9]. 
 
Figure 1. Chemical structure of iron-protoporphryn IX bound via cysteine 
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Most metabolizing P450s are membrane bound enzymes and are centered on an 
iron-protoporphryn IX prosthetic group, which is an active site for oxygen binding. The 
structure of this prosthetic group is shown in Fig. 1. The highest concentration of P450s 
is in liver in mammals, but the P450s have been reported in almost all tissue including 
lung, kidney, colon, intestine and brain [10].  
P450 catalyzes a variety of reactions including epoxidation, N-dealkylation, O-
dealkylation, S-oxidation and hydroxylation. A typical cytochrome P450 catalyzed 
reaction can be represented by the following chemical equation [11]:  
 
NADPH + H+ + O2 + RH ==> NADP+ + H2O + R-OH 
 
In the above equation, RH is an organic substrate and the oxygen atom 
incorporated into the product R-OH is derived from molecular oxygen. NADPH, in the 
equation stands for nicotinamide adenine dinucleotide phosphate in its reduced form. 
This is the biological electron donor to P450 enzymes in the liver [12, 13]. 
The overall reaction occurs in stages that can be described as a cycle. The 
catalytic cycle of Cytochrome P450 can be summarized as shown in Figure 2. The steps 
of the cycle are as follows [14]: 
1. Substrate binding  
The binding of a substrate to a P450 causes a lowering of the redox potential of 
the heme, which makes the transfer of an electron favorable from its redox partner, 
cytochrome P450 reductase, which gets electrons from NADH or NADPH. [15]. 
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2. The first reduction  
The next stage in the cycle is the reduction of the Fe3+ ion by an electron 
transferred from NAD(P)H. 
3. Oxygen binding  
 An O2 molecule binds rapidly to the Fe2+ ion forming Fe2+ O2- [16]. 
4. Second reduction  
A second reduction is required by the stoichiometry of the reaction. This has been 
determined in many instances to be the rate-determining step of the reaction. In fact, there 
is very little direct evidence for the subsequent intermediates in the cycle, because 
relative to this intermediate they are very unstable [17, 18]. 
5. O2 cleavage  
The O2 reacts with two protons from the surrounding solvent, breaking the O-O 
bond, forming water and leaving an (Fe-O) 3+ complex. 
6. Product formation  
The Fe-ligated O atom is transferred to the substrate forming a hydroxylated form 
of the substrate, through an “oxygen rebound” type mechanism. 
7. Product release  
The product is released from the active site of the enzyme which returns to its 
initial state.  
Currently many members of the Cytochrome P450 super-family of hemo-proteins 
are known, and the numbers continue to grow as more genomes are sequenced. There are 
almost 4000 identified P450 genes today. In the broadest terms, there are two main 
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functional roles for these oxygenases. One role is to metabolize foreign chemicals, which 
serves a protective function for the host organism. A second broad functional role is in 
the biosynthesis of critical signaling molecules used for control of development and 
homeostasis. For example, the synthesis of a variety of steroid hormones is carried out by 
Cytochrome P450 family members [19]. 
 
 
 
 
Figure 2. The catalytic cycle of P450 
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1.1.2 Active-Site Structure of P450 Enzymes  
P450 enzymes have a common overall fold and topology despite less than 20% 
sequence identity across the gene super-family. In past years significant progress has 
been made in determining the crystal structures of mammalian P450s. The conserved 
P450 structural core is formed by a four-helix bundle composed of three parallel helices 
labeled D, L, and I and one anti-parallel helix E. The prosthetic heme group is confined 
between the distal I helix and proximal L helix and bound to the adjacent Cys heme-
ligand loop containing the P450 signature amino acid sequence [20]. 
The fold of cytochrome P450s is highly conserved and shown in the ribbon 
representation in Figure 3. Substrate recognition sequence (SRS) regions are shown in 
black and labeled [20]. 
 
Figure 3. Chemical structure of P450 
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1.1.3 Cytochrome P450 2E1 
Cytochrome P450 2E1 is a major cytochrome isoform in the liver and is an 
ethanol-inducible form with broad substrate specificity. It is inducible by a number of 
small organic molecules including therapeutic agents and toxicants. P450 2E1 is an 
enzyme responsible for the metabolic activation of many carcinogens. This enzyme is 
also believed to participate in the oxidation of other compounds, such as ethanol, to 
produce free radicals that may initiate lipid peroxidation and then carcinogenesis. Its 
inhibition effects could have important clinical applications. Table 1 summarizes many 
substrates that can be effectively metabolized by P450 2E1 [21]. 
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Table 1. Substrates metabolized by P450 2E1 
Substrate Product Measured 
Aromatic compounds  
Pyridine 
3-Hydroxypridine 
p-Nitrophenol 
Benzene 
Phenol 
Acetaminophen 
Pyrazole 
Chlorzoxazone 
Styrene 
Anline 
Pyridine N-oxide 
2,5-Dihydroxypyridine 
4-Nitrocatechol 
Phenol 
hydroquinone; catechol 
Glutathione conjugates 
4-Hydroxypyrazole 
6-Hydroxychlorzoxazone 
Glutathione conjugates 
p-Aminophenol 
Halogenated alkanes 
andalkenes/alkanes  
Chloroform 
Pentane 
Chloromethane 
Dibromoethane 
Dibromomethane 
1,2-Dichloropropane 
1,1,1-Trichloroethane 
Trichloroethylene 
Ethylene dibromide 
Ethylene dichloride 
Vinyl chloride 
Vinyl bromide 
Vinyl carbamate 
Enflurane 
Halothane 
1,1,1,2-Tetrafluoroethane 
Glutathione conjugates 
product not measured 
Glutathione conjugates 
Glutathione conjugates 
Glutathione conjugates 
1, N-Ethenoadenosine 
1,1,1-Trichloro-2-hydroxyethane  
Chloral 
1, N-Ethenoadenosine 
1, N-Ethenoadenosine 
1, N-Ethenoadenosine 
1, N-Ethenoadenosine 
1, N-Ethenoadenosine 
Fluoride 
Trifluoroacetic acid 
Fluoride 
Alcohols/ketones/nitriles  
Ethanol 
Propanol 
isopropanol 
Butanol 
Pentanol 
Glycerol 
Acetol 
Acetone 
Acetonitrile 
Acetaldehyde 
Propionaldehyde 
Acetone 
Butylaldehyde 
Valeraldehyde 
Formaldehyde 
Methyglyoxal 
Acetol 
Cyanide 
Ethers  
Diethyl ether 
Methly t-butyl ether 
Acetaldehyde 
Formaldehyde/t-butanol 
Reductive substrate  
Carbon tetrachloride 
Chromium 
t-butylhydroperoxide 
Oxygen 
Lipid peroxidation/chloroform 
Product not measured 
Methane/acetone 
Superoxide/peroxide/water 
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1.2 Inhibition and Induction 
1.2.1 Induction  
Induction is an increased synthesis of enzyme that is associated with exposure to 
drugs. The induction can occur when a drug stimulates the biotransformation of drugs 
either through the same enzyme pathway or via an alternative pathway. However 
inducers are usually specific for a given Cytochrome P450 family [11]. 
1.2.2 Inhibition  
1.2.2.1 Enzyme kinetics 
The Michaelis-Menten model of enzyme kinetics is shown below: 
         K1              K2 
      E + S         ES      E + P 
     K-1 
(Eq. 1) 
Where, E = Enzyme S = Substrate P = Products 
      
1
21
K
KKK m
+
= −                        (Eq. 2) 
Km is the Michaelis constant. 
The maximum velocity, Vmax, is achieved when the enzyme is saturated with 
substrate. Therefore, the Michaelis-Menten equation can be shown in the following form:  
            
           (Eq. 3) 
 
SK
SVV
m +
= max
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 The Lineweaver-Burk equation can be derived from the Michaelis-Menten 
equation by taking the reciprocal of the Velocity and Substrate concentration. The 
equation then takes on the following form: 
maxmax
111
VSV
K
V
m +×=     (Eq. 4)  
Where, Km is the Michaelis constant; S is the substrate concentration and Vmax is 
maximum velocity.  
1.2.2.2 Types of enzyme inhibition 
Many compounds can inhibit enzymes. Highly reactive chemicals can form 
covalent bonds with reactive groups on the enzyme and irreversibly inhibit the enzyme. 
Others interact with the enzyme in reversible ways to produce inhibition. We will 
concentrate here on the reversible inhibitors of enzymes [22].  
1) Competitive inhibition 
Competitive inhibition occurs when a compound has a similar chemical structure 
to the enzyme substrate. The inhibitor interacts with the enzyme to form an unproductive 
enzyme-competitive inhibitor complex. This results in competitive inhibitors increasing 
the value of Km but not affecting Vmax [22].  
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Figure 4. Lineweaver-Burk Plot of competitive inhibition 
 
2)  Noncompetitive inhibition 
Noncompetitive inhibitors bind to the enzyme-substrate complex and block the 
catalytic step. They do not affect Km but decrease Vmax [22]. 
 
  
Figure 5. Lineweaver-Burk Plot of noncompetitive inhibition 
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3)  Uncompetitive inhibition  
 Uncompetitive inhibitors bind to both free enzyme and enzyme-substrate 
complex. They consequently affect both Km and Vmax [22]. 
 
 
Figure 6. Lineweaver-Burk Plot of uncompetitive inhibition 
 
1.3 Natural products with potential influence on P450 systems 
1.3.1 Grapefruit juice 
The grapefruit-drug interaction was discovered accidentally in 1989. Grapefruit 
can interact with a variety of prescription medications. As a widely available fruit source 
to meet daily nutritional requirements, grapefruit juice is consumed by many individuals 
everyday. For the above reasons, researchers need to understand grapefruit-drug 
interaction [23]. The inhibitory constituent of grapefruit juice is furanocoumarin, which 
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exists in various plants that are sometimes used to cure skin diseases. Previous studies 
have shown that furanocoumarins were both significant competitive and mechanism-
based inhibitors of P450 3A4. This enzyme system in the liver is well known for its 
involvement with drug-drug interactions. In addition, different furano-coumarin 
derivatives have been reported to induce or inhibit P450 subtypes such as cytochrome 
P450 (CYP) 1A1, 1A2, 1B1, 2A5, 2A6 etc [24-30]. Grapefruit juice can also change oral 
drug pharmacokinetics by different possible mechanisms. Irreversible inactivation of 
CYP 3A4 is produced by commercial grapefruit juice with a normal amount (e.g. 200-
300 ml) or by whole fresh fruit. As a result, P450-related metabolisms are reduced and 
oral drug bioavailability increased [31]. 
1.3.2 St John’s Wort 
For centuries, St John’s Wort (Hypericum perforatum) has been used as a 
medicinal herb. It has been believed to possess sedative and astringent properties, and 
also has been used traditionally for the treatment of excitability, neuralgia, fibrositis, 
sciatica, anxiety, depression and nerve tonic. Currently, it is best known for its use in the 
treatment of mild-to-severe depressive disorders, but antiviral and antibacerial effects are 
also suggested. One reason for its popularity is that it is freely available over-the-counter 
and another reason is that it is presumed to be safe. However, it has been found to have 
herb-drug interaction with conventional medicines, including digoxin, cyclosporin, 
indinavir, amitriptyline, warfarin. Commercially available St. John’s wort extracts have 
 12
been reported for the potential to inhibit human Cytochrome P450 enzyme activities, 
specifically of CYP 1A2, CYP 2C9, CYP 2C19, CYP 2D6 and CYP 3A4 [32-39].  
1.3.3 Green Tea Extract 
Green tea contains a variety of polyphenols including EGCG (epigallocatechin 
gallate), EGC (epigallocatechin) and EC (epicatechin). Most chemicals are not reactive 
themselves and require metabolism by a variety of enzymes responsible for drug 
metabolism. P450 1A enzymes are known to catalyze the metabolic activation of 
polycyclic aromatic hydrocarbons and aromatic amines. Interest in green tea as a cancer 
preventive agent has increased dramatically over the past 15 years. Animal studies have 
demonstrated that green tea popyphenols inhibit carcinogen-induced tumor in numerous 
tissues, inhibit tumor promotion and decrease tumor size. One mechanism for this may be 
through its ability to inhibit P450 1A enzyme activity or expression [40-48]. 
1.3.4 Goldenseal 
Goldenseal (Hydrastis canadensis) is a popular immuno-stimulant and 
goldenseal-containing herbal supplements rank high among botanical products sold. 
Goldenseal extract contains isoquinoline alkaloids, including berberine, canadine and 
lesser amounts of hydrastine. These three goldenseal alkaloids possess a 
methylenedioxyphenyl (MDP) moiety, which frequently gives rise to inhibition. 
Goldenseal is a slow-growing plant and its root was used to treat diseases, such as 
inflammation and infection of skin. It is frequently combined with Echinacea in treatment 
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of colds and upper respiratory infections. Goldenseal’s widespread popularity is primarily 
due to its antibiotic activity. Goldenseal was identified as a potent inhibitor of P450 3A4 
in previous studies [49-53]. 
1.3.5 Echinacea  
Echinacea, also known as the American coneflower or purple coneflower, has a 
long history of traditional use by native North Americans for its immuno-stimulatory 
properties. Echinacea was considered as a panacea for a variety of diseases, including 
infections, trauma, inflammation, and fever, by the native people of North America [42]. 
In 1997 Echinacea was the number-one-selling herbal supplement in natural food stores 
in the United States. The three major species of Echinacea used medicinally are: E. 
angustifolia, E. pallida, and E. purpurea [50]. E. purpurea has been reported to 
demonstrated mild inhibition of P450 3A4 activity with7-benzyloxy-4-
trifluoromethylcoumarin (BFC) as the model substrate, but it has mild inducing effect in 
the presence of substrate resorufin benzyl ether (Bz Res). Little effect on P450 2D6 and 
moderate inhibition of P450 2C9 was seen with E. purpurea from the report [54-59]. 
1.3.6 Spilanthes 
Spilanthes is a member of the Asteraceae family with over 60 species and is a 
native of the tropics of Africa and South America. Spilanthes acmella is also known as 
the toothache plant. Spilanthes stimulates the flow of salvia which cleanses the mouth 
and enhances immune function. Spilanthes also improves digestion, eases flatulence and 
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helps to overcome nausea and vomiting by its stimulating effect on the salivary glands. 
There is no relative report about its inhibition of P450 super-family [60-63]. 
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1.4 Herb-drug interaction 
The consumption of herbal products in the world is increasing greatly during last 
decade. It has been found that many herbal medications were taken with drugs at the 
same time which can cause critical herb-drug interaction. The general public does not 
know that many health problems can be related with herbal medication. Among these 
herbal products, St. John's wort was the most common product reported in herb-drug 
interactions. Herb-drug interactions involving the human Cytochrome P450 systems are 
normal, and generally result from either enzyme inhibition or induction. Enzyme 
inhibition often involves competition with another drug for enzyme binding sites. 
Enzyme induction occurs when one drug stimulates production of a drug-metabolizing 
enzyme through one of a multitude of biochemical processes. The pharmacologic aspects 
of drug-herb interactions can provide useful information on the risk of interactions [64-
70]. 
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1.5 Proposed Research 
Inhibition of cytochrome P450 2E1 enzymes is a clinical concern because drug 
interactions resulting in impaired drug metabolism can be detrimental and fatal. 
Inhibition of drug metabolism may cause drug overdose. The purpose of this research is 
to determine whether herbal products, such as GTE, Goldenseal, Echinacea and 
Spilanthes, inhibit the catalytic activity of the expressed human P450 2E1 enzymes and 
which fraction or components are responsible for that inhibition. It is very important 
because P450 2E1 is active in both detoxification and activation of many organic 
molecules, and the mechanism of how these herbs affect the activity of P450 2E1 will be 
useful for the scientific society to understand potential herb-drug interaction.  
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CHAPTER II 
 EXPERIMENTAL 
2.1 Materials 
Microsomes from human liver samples were purchased from Moltox Inc. (Boone, 
NC) and frozen at -70°C. P450 2E1, p-nitrophenol and NADPH were purchased from 
Sigma Chemical. Phosphate buffer (pH 7.4) was prepared with potassium phosphate, 
which was purchased from Sigma Chemical. The GTE catechins were purchased from 
sigma and GTE extract was manufactured by Spring Valley (Bohemia, NY) and 
purchased from a local store. The extract of Goldenseal, Echinacea and Spilanthes were 
prepared by the research group of Dr. Nadja B. Cech of UNCG, and the method for these 
preparations is described at chapter 2.3 and 2.4. HPLC-grade acetonitrile and acetic acid 
were purchased from Sigma-Aldrich. 
 
2.2 Preparation and purification of Goldenseal extract and its alkaloid 
components 
Goldenseal samples were purchased from Kentucky, Ohio and North Carolina, 
and the goldenseal extract was made by Dr. Cech’s research group at UNCG. The 
goldenseal root was powdered using a pestle and weighed to 0.001g. Then a 10mL 
aliquot of 100% ethanol was added to each mixture. Samples were sonicated for one hour 
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and then cooled to room temperature. The solvent was evaporated by using a rotory 
evaporation and the concentrated extracts were filtered. Then a 10mL aliquot was added 
to the round bottom flask and it was sonicated for 15 minutes to dissolve residue. Finally 
the solution was transferred to a refrigerator for storage.  
The samples were analyzed using HPLC-ESI-MS. The gradient elution of 
acetonitrile (from 15% to 25% over 25 minutes) and mixed (90% ammonium acetate 
buffer and 10% acetonitrile) buffer (from 85% to 75% over 25 minutes) were conducted. 
Samples were injected on a Prevail C18 column (50mm×2.1mm) with 3um packed silica, 
and the flow rate of solvent is 0.2mL/Min. For the MS, the sheath gas was at 45arb (unit 
for flow rate given by Xcalibur software) and auxiliary gas was at 20arb. The voltage of 
the capillary, ion spray source and tube lens was at 11.00V, 4.5KV, 55 kV respectively.  
 
2.3 Preparation and Purification of Spilanthes and Echinacea extract 
The extracts of Goldenseal, Spilanthes, and Echinacea were prepared by the 
research group of Dr. Nadja B. Cech of UNCG. For purification of the alkylamides, a 
C18 SPE column was first washed with 50mL 100% ethanol and then washed with 50mL 
50% ethanol. Then a sample containing 100mL Echinacea extract was diluted to 200mL 
with DI water, and loaded onto the column using a peristaltic pump. Then the column 
was washed with 100mL 50% ethanol and eluent was collected in 4 Falcon tubes (50mL), 
each tube containing 25mL. Solutions containing 55% and 60% ethanol were then used in 
successive washing steps using the same procedure. The content of each fraction was 
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analyzed by HPLC, in order to locate the various isobutylamides. For the purification of 
Spilanthes, a similar procedure was used except the concentrations of ethanol were 40%, 
50%, 55% and 60%.  
 
2.4 Assay of P450 2E1 (Nitrophenol Hydroxylation Assay) 
The nitrophenol hydroxylation assay was used for determining the inhibition for 
all four different herbal products, which are GTE, Goldenseal, Echinacea and Spilanthes.  
For inhibition experiments using Green Tea Extract, reaction mixtures (total 
volume: 1000uL) containing 2uL expressed P450 2E1, 50uL NADPH, 100uL buffer and 
GTE (50-750uL of a 25mg/mL sample) were incubated at 37°C for 20 min before the 
reaction was stopped by adding 100uL 6% perchloric acid (v/v). After quenching, 
samples were then placed on ice for 10 min, followed by centrifugation for 10 min at 
8,000 rpm. Supernatants were transferred to autosampler vials for HPLC analysis. A C18 
HPLC column was used with a mobile phase consisting of 70% C (0.5% acetic acid in 
H2O) and 30% D (0.5% acetic acid in acetonitrile), with a column flow rate of 1mL/min. 
The product nitrocatechol was detected at 350 nm. In addition, experiments with GTE 
(Green Tea Extract), the individual catechins, EGCG, EGC and EC, were tested for their 
ability to inhibit P450 2E1 using an identical procedure.  
For Goldenseal, Echinacea and Spilanthes, reaction mixtures (total volume: 
250uL) containing 2.5uL expressed P450 2E1, 12.5uL NADPH, 25ul buffer and Inhibitor 
(0-50uL stock solution) were incubated at 37°C for 30 min before the reaction was 
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stopped by adding 50uL 6% perchloric acid (v/v). After quenching, samples were then 
placed on ice for 10 min, followed by centrifugation for 10 min at 8,000 rpm. 
Supernatants were transferred to autosampler vials for HPLC analysis. A C18 HPLC 
column was used with a mobile phase consisting of 70% C (0.5% acetic acid in H2O) and 
30% D (0.5% acetic acid in acetonitrile), with a column flow rate of 1mL/min. The 
product nitrocatechol was detected at 350 nm.  
The HPLC system used was Shimadzu and consisted of a personal computer 
interfaced to an SCL-10Avp controller. Samples were injected into the C18 column 
(4.6mm×250mm) at a flow rate of 1 ml/min by using the SIL-10ADvp autosampler. The 
Shimadzu SPD-10Avp UV/Visible detector was used for detection of product at 350nm. 
The designated peak areas were calculated and concentrations were determined by using 
the standard curve. Finally, the Vmax and Km were calculated by using the Slidewrite 
Plus software.  
 
2.5 Data processing 
The apparent kinetic constants (Vmax, Km) were determined by the non linear 
regression Enzyme Kinetics program from Slidewrite Plus.  
When only a single concentration of substrate and inhibitor were examined, the Ki 
values for each of the competitive inhibitors were calculated from the following formula:  
)(max SKVSV
KIVK
m
m
i +∗−∗
∗∗
=    (Eq. 5) 
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Where Ki is the inhibition constant, V is the rate of reaction in presence of 
inhibitor [I] at substrate [S], and Km and the Vmax are the Michaelis constants for a given 
reaction. The concentration of substrate is assumed to be constant since the high 
concentration of substrate is used compared with the concentration of inhibitor.  
When a compound inhibits an enzyme competitively, it increases the Km for the 
reaction without decreasing the Vmax. In other words, the effect of a competitive inhibitor 
can be overcome by increasing the substrate concentration. 
 The Ki values for noncompetitive inhibitors were calculated from the following 
formula: 
)(
)(
max SKVSV
SKIV
K
m
m
i +∗−∗
+∗∗
=     (Eq. 6) 
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CHAPTER III 
 RESULTS 
3.1 Results of Green Tea Extract (GTE)  
 
Table 2-5 shows the raw activity and inhibition data for the complete GTE and the 
catechins, EGCG (epigallocatechin gallate), EGC (epigallocatechin) and EC (epicatechin) 
with respect to P450 2E1 activity. Values represented in the tables and graphs are peak 
areas of the product in the reaction of p-nitrophenol with P450 2E1. The peak areas are 
directly proportional to the velocity of the reaction. 
3.1.1 EGCG (100ug/mL)  
Table 2. The values of concentration of product (nitrocatechol) with and without potential 
inhibitor of EGCG 
Substrate (uM) 
 
Product w/ inhibitor   
(ug/mL) 
Product w/o inhibitor 
(ug/mL) 
10 0.478122 0.473755 
20 0.604760 0.674629 
40 0.652795 0.844934 
60 0.766332 0.967205 
80 0.665895 0.971572 
100 0.980306 1.172445 
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3.1.2. EGC (100ug/mL) 
Table 3. The values of concentration of product (nitrocatechol) with and without potential 
inhibitor of EGC 
Substrate (uM) 
 
Product w/ inhibitor   
(ug/mL) 
Product w/o inhibitor 
(ug/mL) 
10 0.657162 0.709563 
20 0.779432 1.032707 
40 0.989039 1.089476 
60 0.805633 0.884236 
80 0.853668 0.954105 
100 0.853668 0.975939 
 
3.1.3 EC: (100ug/mL) 
Table 4.The values of concentration of product (nitrocatechol) with and without potential 
inhibitor of EC 
Substrate (uM) 
 
Product w/ inhibitor    
(ug/mL) 
Product w/o inhibitor 
(ug/mL) 
10 3.355852 3.783799 
20 4.526157 4.792533 
40 5.412620 5.661528 
60 5.465022 6.303450 
80 5.451921 6.220480 
100 5.840568 6.661528 
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3.1.4. GTE (100ug/mL) 
Table 5. The values of concentration of product (nitrocatechol) with and without potential 
inhibitor of GTE 
Substrate (uM) 
 
Product w/ inhibitor     
(ug/mL) 
Product w/o inhibitor 
(ug/mL) 
10 1.971572 3.971572 
20 2.390786 4.015240 
40 3.478122 4.670262 
60 3.814367 4.980306 
80 3.858035 6.054541 
100 3.884236 6.141878 
 
 
Four different inhibitors were examined by using the nitrophenol assay, which 
was described in the previous chapter. From the above data, all four inhibitor clearly 
didn’t inhibit the activities of P450 2E1 very much. Only GTE showed some inhibition of 
enzyme P450 2E1, but it is still not potent. Therefore we could draw a conclusion that the 
GTE and its components don’t inhibit the activities of P450 2E1 and the kinetic 
parameters such as Km, Vmax and Ki don’t need to be calculated.  
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3.2 Results of Goldenseal 
Figure 7-10 shows the inhibition by goldenseal and the individual alkaloids 
Canadine, Hydrastine and Berberine with respect to P450 2E1 activity. Values 
represented in graphs are velocities of the product in the reaction of p-nitrophenol with 
P450 2E1. Experiments were run at two different inhibitor concentrations, 100 μM and 4 
μM. The standard curve of nitrocatechol was prepared in which nitrocatechol was plotted 
versus peak area. The resulting linear equation was used to correlate area to product. 
y=23900x+1551, where x means concentration (µM) and y means peak area. 
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3.2.1 Inhibition effect on P450 2E1 with the potential inhibitor (100µM) 
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Figure 7. Michaelis-Menten plot of nitrophenol oxidation by 2E1 and inhibition by 
goldenseal components. Each data point is the average from two samples. 
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Figure 8. Lineweaver Burk plot of nitrophenol oxidation by 2E1 and inhibition by 
goldenseal components. Each data point is the average from two samples. 
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Figure 8 and 9 sumarizes the results of inhibition studies carried out using each of 
the main alkoloid components of a goldenseal extract, such as hydrastine, canadine and 
berberine, each at a concentration of 100 μM.  As indicated by the Michaelis-Menten 
curve, each component was capable of inhibiting P4502E1 activity in human liver 
microsomes significantly. Hydrastine appeared to be the most potent inhibitor among 
these three components of Goldenseal. The data displayed in this figure was analyzed 
using the Michaelis-Menten model for enzyme inhibition, and the kinetic parameters such 
as Km, Vmax are summarized in table 6. From this data table, berberine appears to be 
noncompetitive inhibitor because it has very similar Km with that of the control. Canadine 
and hydrastine appear to be competitive inhibitors with different Ki value. The Ki value 
of 86uM of hydrastine indicates that hydrastine is the most potent inhibitor on P450 
2E1’s activities. 
Ki can be calculated from the following equations: 
Competitive Inhibitor: Km' = Km * (1 + [I]/Ki) 
Non-Competitive Inhibitor: Vmax' = Vmax/(1 + [I]/Ki) 
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3.2.2 Inhibition effect on P450 2E1 with the potential inhibitor (4uM) 
0 32 64 96 128 160
pNP (uM)
0.00
0.03
0.06
0.09
0.12
0.15
V
el
oc
ity
 (u
M
/M
in
)
Berberine Canadine Hydrastine No inhibitor
 
Figure 9. Michaelis-Menten plot of nitrophenol oxidation by 2E1 and inhibition by 
goldenseal components. Each data point is the average from two samples. 
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Figure 10. Lineweaver Burk plot of nitrophenol oxidation by 2E1 and inhibition by 
goldenseal components. Each data point is the average from two samples. 
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Figure 10 and 11 summarize the results of inhibition studies carried out using 
each of the main alkaloid components of a goldenseal extract (hydrastine, canadine and 
berberine), each at a concentration of 4uM. As indicated by the Michaelis-Menten curve, 
each component was capable of inhibiting P450 2E1 activity in human liver microsomes 
significantly. Of the three compounds tested, hydrastine appeared to be the most potent. 
The data displayed in this figure was analyzed using the Michaelis-Menten model for 
enzyme inhibition, and Ki values for each of the compounds were determined. These 
values are summarized in table 6. As seen from this table of goldenseal, Berberine and 
Canadine appear to be noncompetitive inhibitors since they have similar Km with that of 
the control and the Ki are 18.4uM and 16.9 uM respectively. For hydrastine, it could have 
mixed inhibition. A Ki value of 3.2 uM for hydrastine indicates that this compound is the 
most potent inhibitor of P450 2E1. 
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Table 6. The values of inhibition constant (Ki), Maximum Velocity (Vmax) and Michaelis 
Constant (Km) for P450 2E1 in the presence of Goldenseal components (4µM and 100µM) 
 
 
Vmax 
 (µM/Min) 
Km 
(µM) 
Ki 
(µM) 
Berberine (4µM) 0.129±0.092 47.4±10.8 18.4 
Canadine (4µM) 0.127±0.089 39.0±6.51 16.9  
Hydrastine (4µM) 0.070±0.004 35.4±5.83 3.20 
Control 0.157±0.097 50.5±11.6 N/A 
Berberine (100µM) 0.062±0.003 28.5±4.79 132 
Canadine (100µM) 0.090±0.005 45.9±10.2 144 
Hydrastine (100µM) 0.077±0.004 58.8±11.9 86 
Control 0.109±0.077 27.1±5.72 N/A 
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3.3 Results of Echinacea 
Figure 11-17 represents inhibition data for Echinacea and the individual fraction 
with respect to P4502E1 activity. Values represented in the graphs are velocities of the 
product in the reaction of p-nitrophenol with P450 2E1. The standard curve used to 
calculate alkylamide concentrations in Echinacea gave the following linear equation 
y=2120x-30883, where x means concentration (µM) and y means peak area (Table 7). 
The fractions 1 to 4 are the eluent by using 50% ethanol washing (method was described 
in chapter 2.3). The fractions 5 to 6 are the eluent by using 55% ethanol washing, and the 
method also was described in chapter 2.3. 
The standard curve of isobutylamide can be calculated from the following table. 
 
Table 7. The peak area of different concentration of isobutylamide 
Number Concentration (µM) Peak Area 
1 1000 2099800 
2 500 1010700 
3 250 481800 
4 100 205600 
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3.3.1 Fraction 1  
The results of fraction 1 show that the activities of P450 2E1 are almost 
completely inhibited because the concentrations of product are very low, therefore 
Michaelis-Menten plots could not be prepared.  
3.3.2 Fraction 2 
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Figure 11. Michaelis-Menten plot of nitrophenol oxidation by 2E1 and inhibition by 
Echinacea fraction 2. Each data point is the average from two samples. 
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The ability of Echinacea fraction 2 to alter the 2E1 enzymatic activities is shown 
in Figure 11. From this Michaelis-Menten curve, fraction 2 of Echinacea was capable of 
inhibiting the P450 2E1 activities greatly. Five pNP (substrate) (10-80µM) concentrations 
were used. 
3.3.3 Fraction 3 
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Figure 12. Michaelis-Menten plot of nitrophenol oxidation by 2E1 and inhibition by 
Echinacea fraction 3 
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Figure 12 indicates the inhibition effects of fraction 3 of Echinacea by using pNP 
assay, which is described in the previous chapter. From Figure 12, fraction 3 of 
Echinacea was also shown that it could greatly inhibit the P450 2E1 activities, and it has 
the similar inhibition effect on 2E1 with that of fraction 2.  
3.3.4 Fraction 4  
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Figure 13. Michaelis-Menten plot of nitrophenol oxidation by 2E1 and inhibition by 
Echinacea fraction 4 
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The ability of Echinacea fraction 4 to alter the 2E1 enzymatic activities is shown 
in Figure 13. From this Michaelis-Menten plot, fraction 4 of Echinacea was able to 
inhibit the P450 2E1 activities greatly. The inhibition on P450 2E1 was similar to that of 
fraction 2 and fraction 3. The Lineweaver-Burk Plot of these three fractions will be 
plotted in the same graph to determine their relationship to control. 
3.3.5 Fraction 5  
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Figure 14. Michaelis-Menten plot of nitrophenol oxidation by 2E1 and inhibition by 
Echinacea fraction 5 
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Figure 14 indicates the inhibition effects of fraction 5 of Echinacea by using pNP 
assay. From this Michaelis-Menten curve, it shows that fraction 5 of Echinacea was 
capable of inhibiting the P450 2E1 activities to some extend, but is not as much as that of 
above three fractions 2, 3, 4. It can also be seen that the concentration of P450 2E1 
inhibitor in fraction 5 is decreased. 
3.3.6 Fraction 6  
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Figure 15. Michaelis-Menten plot of nitrophenol oxidation by 2E1 and inhibition by 
Echinacea fraction 6 
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The ability of Echinacea fraction 6 to alter the 2E1 enzymatic activities is shown 
in Figure 15. From this Michaelis-Menten plot, fraction 6 of Echinacea could inhibit the 
P450 2E1 activities to some extend. It has the least inhibition effect on P450 2E1 among 
these 5 fractions of Echinacea. The Lineweaver Burk Plot of fraction 4, 5, 6 will be 
plotted in the same graph to determine their relationship to control experiment. 
3.3.7 Control  
Table 8. The values of V(Velocity), Substrate(S), 1/V, and 1/S of control of Echinacea 
Peak Area 
control 
X 
(uM) 
Velocity 
(uM/Min) 
1/V 
(Min/uM) 
S 
(uM) 
1/S 
(1/uM) 
18300 23.19953 4.342042 0.230306 10 0.1000 
32300 29.8033 5.578009 0.179275 20 0.0500 
49850 38.0816 7.127382 0.140304 40 0.0250 
67050 46.19481 8.645857 0.115662 60 0.0167 
72400 48.7184 9.118173 0.109671 80 0.0125 
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3.3.8 Comparison of fraction 2 3 4 with control 
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Figure 16. Michaelis-Menten plot of nitrophenol oxidation by 2E1 and inhibition by 
Echinacea fraction 2 3 4 
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The comparison of the ability of Echinacea fraction 2, 3, 4 to alter the 2E1 
enzymatic activities is shown in Figure 16. Figure 16 is the Michaelis-Menten plot of 
these three fractions of Echinacea. The pNP assay was used for all three factions 
experiments. From this Michaelis-Menten curve, it appears that fraction 2, 3, 4 of 
Echinacea were capable of inhibiting the P450 2E1 activities greatly and it also can be 
seen that the fraction 2, 3, 4 have very similar inhibition effect on P450 2E1. From table 9, 
it appears that it is the mixed inhibition on P450 2E1 for fraction 3 of Echinacea because 
each of these fractions has different Vmax and Ki from that of control. The fraction 2 and 4 
appears to show the competitive inhibition on P450 2E1 activity since they have similar 
Vmax with that of control.  
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3.3.9 Comparison of 4 5 6 with control 
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Figure 17. Michaelis Menten plot of nitrophenol oxidation by 2E1 and inhibition by 
Echinacea fraction 4, 5, 6 
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Figure 17 indicates the results of the comparison of inhibition effects of fraction 4, 
5, 6 of Echinacea by using pNP assay, which is described in the previous chapter. Figure 
17 is the Michaelis-Menten plot of these three fractions of Echinacea. From Figure 17, it 
appears that fraction 4, 5, 6 of Echinacea were capable of inhibiting the P450 2E1 
activities to some extend, while fraction 6 has the least inhibition effect on P450 2E1. 
From table 9, it appears that fraction 6 of Echinacea shows the mixed inhibition on P450 
2E1, while fraction 5 shows the competitive inhibition on P450 2E1. 
 
Table 9. Values of Maximum Velocity (Vmax) and Michaelis Constant (Km) of the 
fractions of Echinacea 
 
Number (Echinacea) Vmax (uM/Min) Km (uM) 
Fraction 1 N/A N/A 
Fraction 2 0.245±0.035 1076±479 
Fraction 3 0.091±0.008 411±271 
Fraction 4 0.237±0.033 947±454 
Fraction 5 0.143±0.027 355±207 
Fraction 6 0.523±0.064 751±363 
Control 0.186±0.029 67.3±17.0 
 
 
 
 
 44
3.4 Results of Spilanthes 
The experimental method of Spilanthes is pNP assay which was described in the 
previous chapter. The following tables and graphs represent inhibition data for Spilanthes 
and the individual fraction with respect to P4502E1 activity. Values represented in the 
tables and graphs are peak areas of the product in the reaction of p-nitrophenol with 
P450. The standard curve for nitrocatechol used in the Spilanthes experiments is 
described by the following linear equation: y=2120x-30883, where x means 
concentration (µM) and y means peak area. The fraction 1 and 2 are the eluent by using 
40% ethanol washing, which method was described in chapter 2.4. The fraction 3 to 5 are 
the eluent by using 50% ethanol washing, the fraction 7 to 9 are the eluent by using 55% 
ethanol washing and the fraction 10 to 12 are the eluent by using 60% ethanol washing.  
3.4.1 Fraction 1, 2, 3 
The experiments of these fractions were carried out by using pNP assay, but the 
peak of products overlapped with other peaks. Several different techniques were used to 
separate these peaks, such as using longer HPLC column and changing the mobile 
composition. Unfortunately, these peaks were still overlapped, therefore the data of these 
experiments were blank. 
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3.4.2 Fraction 4 
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Figure 18. Michaelis Menten plot of nitrophenol oxidation by 2E1 and inhibition by 
Spilanthes fraction 4 
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Figure 19. Lineweaver Burk plot of nitrophenol oxidation by 2E1 and inhibition by 
Spilanthes fraction 4 
 
Figure 18, 19 indicates the inhibition effects of fraction 4 of Spilanthes on the 
pNP assay, which is described in the previous chapter. Figure 18 and Figure 19 are the 
Michaelis-Menten plot and the Lineweaver-Burk plot of fraction 4 of Spilanthes, 
respectively. From these two plots, it appears that fraction 4 of Spilanthes was capable of 
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inhibiting the P450 2E1 activities greatly. The competitive inhibition could be also 
concluded from the Figure 19 since fraction 4 has similar Vmax with that of control, which 
are 0.114 µM/Min and 0.159µM/Min respectively. 
3.4.3 Fraction 5 
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Figure 20. Michaelis Menten plot of nitrophenol oxidation by 2E1 and inhibition by 
Spilanthes fraction 5 
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Figure 21. Lineweaver Burk plot of nitrophenol oxidation by 2E1 and inhibition by 
Spilanthes fraction 5 
 
Similarly, Figure 20 and 21 indicates the results of inhibition effects of fraction 5 
of Spilanthes by using pNP assay. From Figure 20, it can be seen that fraction 5 of 
Spilanthes could inhibit P450 2E1 activities greatly. From Figure 21 and Table 10, it 
appears that this fraction has competitive inhibition on P450 2E1’s activities because they 
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have similar Vmax value with that of control, 0.072uM/Min and 0.098uM/Min 
respectively. 
3.4.4 Fraction 8  
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Figure 22. Michaelis Menten plot of nitrophenol oxidation by 2E1 and inhibition by 
Spilanthes fraction 8 
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Figure 23. Lineweaver Burk plot of nitrophenol oxidation by 2E1 and inhibition by 
Spilanthes fraction 8 
 
Figure 22, 23 indicates the results of inhibition effects of fraction 8 of Spilanthes 
by using pNP assay. The Michaelis-Menten plot and the Lineweaver Burk plot of fraction 
5 of Spilanthes were showed in Figure 22 and Figure 23 respectively. From the above 
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two figures, it can be known that fraction 8 of Spilanthes showed a little inhibition on the 
activities of P450 2E1. We also cannot know what type of inhibition occurs since it has 
similar value of both Km and Vmax.  
3.4.5 Fraction 9 
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Figure 24. Michaelis Menten plot of nitrophenol oxidation by 2E1 and inhibition by 
Spilanthes fraction 9 
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Figure 25. Lineweaver Burk plot of nitrophenol oxidation by 2E1 and inhibition by 
Spilanthes fraction 9 
 
Figure 24 and Figure 25 showed the inhibition effects on 2E1 of fraction 9 of 
Spilanthes. Figure 24 is Michaelis-Menten plot and Figure 25 is Lineweaver-Burk plot of 
fraction 9 of Spilanthes. There is a little inhibition effect on 2E1 of fraction 9 which can 
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be seen from Figure 24. From Table 10, the competitive inhibitor can be determined 
because the Vmax of fraction 9 and control are 0.225 µM/Min and 0.181µM/Min.  
3.4.6 Fraction 10 
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Figure 26. Michaelis Menten plot of nitrophenol oxidation by 2E1 and inhibition by 
Spilanthes fraction 10 
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Figure 27. Lineweaver-Burk plot of nitrophenol oxidation by 2E1 and inhibition by 
Spilanthes fraction 10 
 
Very similar to fraction 9 of Spilanthes, there is a little inhibition effect on 2E1 of 
fraction 10 which can be seen from Figure 26. From Table 10, the competitive inhibition 
 55
can be determined because the Vmax of fraction 10 and control are 0.151uM/Min and 
0.158uM/Min respectively.  
3.4.7 Compared 2E1 with microsome of Fraction 4 
Since fraction 4 has great inhibition effect on P450 2E1’s activity, the comparison 
of fraction 4’s inhibition on P450 2E1 and Human Microsome was examined.  
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Figure 28. Michaelis Menten plot of nitrophenol oxidation by 2E1 and human microsome, 
and inhibition by Spilanthes fraction 4 
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Figure 29. Lineweaver-Burk plot of nitrophenol oxidation by 2E1 and human microsome, 
and inhibition by Spilanthes fraction 4 
 
 
Figure 28, 29 indicates the results of the comparison of inhibition effects of 
fraction 4 of Spilanthes on P450 2E1 and human microsome. From this Michaelis-
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Menten plot, fraction 4 of Spilanthes has the similar inhibition on the activities of P450 
2E1, while fraction 4 has a little more inhibition on P450 2E1 activity than that of human 
microsomes. From Figure 29, the type of inhibition cannot be determined from this plot 
because it has different Km and Vmax values. 
 
Table 10. The values of Vmax and Km of different fractions of Spilanthes 
 
 Control 
Fraction # Vmax (uM/Min) Km (uM) Vmax (uM/Min) Km (uM) 
4 0.114±0.020 70.65±13.9 0.159±0.023 26.98±5.37 
5 0.072±0.018 350.7±152 0.098±0.019 35.10±3.69 
8 0.137±0.028 32.89±5.95 0.158±0.027 36.35±3.64 
9 0.225±0.039 75.54±14.3 0.181±0.032 39.35±4.06 
10 0.151±0.024 35.96±6.17 0.158±0.026 26.98±5.31 
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CHAPTER IV 
 DISCUSSION  
4.1 Summary of Objectives 
P450 2E1 activities were to be examined with respect to inhibition by four 
potential different inhibitors, including GTE, Goldenseal, Echinacea and Spilanthes. The 
concentration of each isobutylamide would be estimated using HPLC to generate a 
standard curve for a commercially available isobutyl amide. This standard curve could 
then be used to quantify all of the different isobutylamides in their purified forms. 
Inhibition experiments were performed in which different inhibitors were included in the 
reaction mixtures. The activities were compared to reactions that were with no inhibitor 
present. The inhibition constants then were calculated from Michaelis-Menten plots. The 
kinetic parameters obtained for all of these experiments, including Vmax and Km, were 
calculated for each experiment. The activity of individual fractions of GTE, Goldenseal, 
Echinacea and Spilanthes were determined to see which fraction could play an important 
role in this inhibition. 
 
4.2 Green Tea Extract (GTE) 
Four constituents of GTE, including EGCG, EGC, EC and GTE, were examined 
for their ability to block 2E1 activity by using pNP assay. The concentrations of all four 
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inhibitor were 100ug/mL and the concentration of substrate was increased from 10uM to 
100uM. From the data of green tea extract, all of them clearly didn’t inhibit the activities 
of P450 2E1 very much. Only whole extract showed more inhibition on the activities of 
enzyme P450 2E1, but it was still not significant. We may conclude that there are no 
significant inhibitions inhibitors present in GTE, since the concentration used was very 
high (100ug/mL). The present data of GTE have been shown that the GTE and its 
components don’t inhibit the activities of P450 2E1. For the future, other P450 enzymes, 
such as 3A4, can be used to measure the inhibition effects of GTE and its components.  
 
4.3 Goldenseal 
Compared with GTE, the components of Goldenseal appear to show much more 
inhibition on the activities of P450 2E1. As indicated by the Michaelis-Menten curves, 
each component was capable of inhibiting P4502E1 activity significantly, even at low 
micromolar concentration. From the table 14, it indicates that the inhibitions of berberine 
and canadine are noncompetitive when the inhibitor’s concentration is 4uM. Among 
these inhibitors, hydrastine appears to be the most potent inhibitor. This can be known 
from the inhibition constant of hydrastine, Ki = 3.2uM, while the Ki values of Berberine 
and Canadine are 18.4uM and 16.9uM respectively. Although Berberine and Canadine 
had been shown to inhibit P450 2E1 activity, their inhibitory effects were about one order 
of magnitude weaker than that of hydrastine. When the inhibitor’s concentration is 
100uM, berberine appears to be noncompetitive inhibitor while canadine and hydrastine 
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appear to be noncompetitive inhibitors. The Ki value of 86uM of hydrastine indicates that 
hydrastine is the most potent inhibitor on P450 2E1’s activities. These kinetic data (Ki) 
strongly suggest that hydrastine is the most potent inhibitor among the components of 
Goldenseal investigated. We propose that hydrastine may be a strong enough inhibitor to 
exert effects in vivo. Although it is unknown how much of this compound may reach the 
liver, the low Ki value indicates further study is wanted. 
Overall, it is evident that all three components of Goldenseal are capable of 
inhibiting the activity of P450 2E1 and hydrastine is the most potent inhibitor among all 
components. These observations support the concept that ingestion of goldenseal extract 
could potentially inhibit the metabolism of many drugs currently in therapeutic use. 
 
4.4 Echinacea 
The inhibition effects of Echinacea were examined by using pNP assay, which is 
described in the previous chapter. The comparisons of 6 different fractions of Echinacea 
were listed in chapter 3.3. The data of Echinacea indicates that all fractions are capable of 
inhibiting the activities of P450 2E1 at relatively high concentrations and fractions 2, 3, 4 
are showing the most potent inhibition on P450 2E1’s activities. From table 9, it can be 
seen that both Vmax and Km of the control are different from that of fraction 3, 6 of 
Echinacea. It indicates that the inhibitions are not strictly competitive or noncompetitive; 
rather it is possible that the inhibition is a mixture of competitive and noncompetitive 
inhibition. The competitive inhibition of fractions 2, 4 and 5 on P450 2E1 can be seen 
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from table 9. It appears that fraction 1 of Echinacea has the most significant inhibition on 
P450 2E1. It killed all activities of P450 2E1, and this may be caused by the high 
concentration of isobutylamide of Echinacea in fraction 1. From the comparison of 
fraction 2, 3, 4 of Echinacea, it is clear that these three fractions have the similar 
inhibition on the activities of P450 2E1. This also can be seen from kinetic parameter 
data in table 9. The Vmax and Km values were calculated from the Michaelis-MentenPlot 
by using Slidewrite Plus software.  
In summary, the inhibition of P450 2E1 was observed in all fractions of 
Echinacea in the present study. Fraction 1 is the most potent compound inhibiting the 
activities of P450 2E1 at the concentration present in the extract, and fraction 2, 3, 4 have 
the similar inhibition effects on P450 2E1. The competitive inhibition of fraction 2, 4 and 
5 of Echinacea could be determined on P450 2E1 activity, while fraction 3 and 6 appear 
to show the mixed inhibition on P450 2E1 activity. The results of these experiments give 
useful information to the scientific communities on the potential for inhibition of 
metabolic enzymes by herbal products, such as Echinacea. 
 
4.5 Spilanthes 
The pNP assay was used to determine the inhibition effects of fractions of 
Spilanthes on P450 2E1. Several fractions resulting from the separation of isobutylamides 
from Spilanthes were examined with respect to their inhibition of P450 2E1 as detailed in 
Chapter 3.4. From the plots and data of Spilanthes, it is clear that the fraction 4 has the 
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most potent inhibition on the activities of P450 2E1, and fraction 4 contains the 
isobutylamides spilanthol. It can be also seen that fraction 8, 9, 10 showed little inhibition 
on the activities of P450 2E1. For fraction 1, 2, 3, the data were not shown in this thesis 
because the product peak overlapped with other peaks and they cannot be separated using 
different mobile phase conditions. Since the fraction 4 had the most potent inhibition on 
P450 2E1, the kinetic parameters of inhibition of P450 2E1 in microsome were 
determined using the Michaelis-Menten model. From table 10, similar inhibition can be 
seen from the data, while fraction 4 has a little more inhibition on the activities of P450 
2E1. The inhibition types of fraction 4, 5, 9 and 10 of Spilanthes on P450 2E1 appear to 
be the competitive inhibition, while fraction 8 of Spilanthes could not be determined. 
This study provides evidence that fraction 4 from the Spilanthes ethanol extract 
had the most potent inhibition on the activities of P450 2E1. The Km and Vmax values of 
Spilanthes determined in this study should be useful in elucidating the extent to which 
this herbal product may influence the metabolism of drugs by cytochrome P450 2E1.  
 
4.6 Improvements and Future Work 
 Since the product peaks of fraction 1, 2, 3 of Spilanthes were overlapped with 
other peaks, more techniques should be used to separate these peaks. For HPLC 
instrument, some samples are in autosampler for up to 20 hours and this could change the 
activity of samples. In order to get better results, all samples should be analyzed at the 
same time.  
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The inhibition effects of GTE and its components EGCG, EGC, EC were 
examined in this study, however they didn’t inhibit significant on P450 2E1 activity. We 
will examine GTE and its major components in their ability to inhibit p-nitrophenol 
oxidation by other isoforms of P450, such as 2D6, 3A4 etc.  
For Echinacea and Spilanthes, future studies involving isolated alkylamides will 
be carried out using samples prepared from both Echinacea and Spilanthes. The 
concentration of each alkylamides would be estimated by using HPLC. The objective is 
to purify enough each component of Echinacea and Spilanthes to calculate Ki values and 
to compare these Ki values to actual concentrations in different extracts. Further studies 
will be designed to examine potential interaction of these compounds with other P450 
isoforms such as 3A4, 2D6, 2A6, 2C8, 1A1 and others. 
 
4.7 Conclusion 
GTE only show some inhibition effects on the activities of P450 2E1 even though 
the inhibition concentration is high enough (100ug/mL), but catechins of GTE did not 
show too much inhibition on P 450 2E1 activity. The inhibition of activities on other 
families of P450 can be examined in the future.  
All three components of Goldenseal are capable of inhibiting of the activities of 
P4502E1 and the hydrastine has the most inhibition effects on the activities of P450 2E1, 
which can be seen from the lowest Ki of hydrastine. From kinetic data of goldenseal, it 
appears that components canadine and berberine are noncompetitive inhibitors of P450 
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2E1 in lower inhibitor concentration (4uM). Berberine appears to be noncompetitive 
inhibitor and canadine and hydrastine appear to be competitive inhibition in higher 
inhibitor concentration (100uM). 
All fractions of Echinacea have inhibition effects on the activities of P450 2E1 
and fraction 1 is the most inhibiting compound on the activities of P450 2E1 among all 
these six fractions. Fractions 2, 4, 5 of Echinacea appears to be competitive inhibitors for 
P450 2E1, while fractions 3 and 6 of Echinacea could have mixed inhibition on P450 
2E1’s activity. 
From kinetic data of Spilanthes, it indicated that fraction 4, 5, 9 and 10 of 
Spilanthes showed competitive inhibition on P450 2E1’s activity. Fraction 4 of 
Spilanthes had the most inhibition effects on the activities of P450 2E1. By comparing 
the fraction 4’s inhibition on 2E1 and human microsomes, similar inhibition can be seen 
from the data and plots of fraction 4. In this study, the herbal products showed different 
extents of inhibition on P450 2E1, and it was successfully determined GTE did not show 
too much inhibition on P450 2E1’s activities and Goldenseal, especially hydrastine, had 
good inhibition effect on P450 2E1’s activities, and also Echinacea and Spilanthes 
showed the interesting inhibition effects varied from different fractions.  
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